Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,675 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Excision Clear all
Recruiting Not applicable Interventional

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

NCT07680283
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
IOUS-guided margin selection
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

NCT00040651
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis
Interventions
Fludarabine, Cyclophosphamide, Thymoglobulin, Leukapheresis, Self bone marrow transplant
Drug · Procedure
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 18, 2026, 5:21 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

NCT01220583
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
259
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

NCT07172256
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
Interventions
CUE-101, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Results available

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

NCT00199888
View directory record Official record
Conditions
Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney, Renal Neoplasms, Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma
Interventions
124-Iodine-cG250 (124I-cG250)
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 4 Interventional Results available

Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

NCT04347122
View directory record Official record
Conditions
Musculoskeletal Cancer, Sarcoma,Soft Tissue
Interventions
Tranexamic Acid (TXA)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

NCT03126539
View directory record Official record
Conditions
Aging
Interventions
Sulforaphane, Narrow-band Ultraviolet B exposure, 4 mm skin punch biopsy
Drug · Radiation · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 18, 2026, 5:21 PM EDT
Active, not recruiting Phase 1 Interventional

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

NCT04420975
View directory record Official record
Conditions
Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma
Interventions
Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab, Radiation Therapy
Procedure · Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

NCT03834961
View directory record Official record
Conditions
Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

NCT01938729
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
Interventions
Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE, GEMCITABINE
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

KingVision Video Laryngoscopy vs Direct Laryngoscopy - Equivalence Trial

NCT02590237
View directory record Official record
Conditions
Tracheal Intubation
Interventions
Ambu KingVision Video Laryngoscope aBlade, Miller Direct Laryngoscopy
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 2 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

NCT00624650
View directory record Official record
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 18, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

Transcriptomic Profile Changes in Benign Tracheal Stenosis: Wedge Resection vs. Radial Incision

NCT07463742
View directory record Official record
Conditions
Tracheal Stenosis
Interventions
Bronchoscopy, carbon dioxide (CO2) laser wedge resection, Radial incision with dilation
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 3 Interventional

PleuraSeal Pivotal Study (US)

NCT00748124
View directory record Official record
Conditions
Open Thoracotomy
Interventions
PleuraSeal Sealant System, Standard Tissue Closure Techniques
Device · Procedure
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

NCT00130780
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 18, 2026, 5:21 PM EDT
Enrolling by invitation Not applicable Interventional

Optimal Duration of Foley Catheter After Bulbar Urethroplasty

NCT07220980
View directory record Official record
Conditions
Urethral Stricture, Bulbar
Interventions
Early catheter removal, Later catheter removal
Device
Lead sponsor
Jane Kurtzman
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Burlington, Massachusetts • Buffalo, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Suspended Not applicable Interventional

Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

NCT06672510
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
ATC
Device
Lead sponsor
Akura Medical
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Thousand Oaks, California • Hartford, Connecticut • Bradenton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

NCT05844527
View directory record Official record
Conditions
Wound of Skin, Abdominal Wound
Interventions
MRG-001, Saline
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 18, 2026, 5:21 PM EDT
Active, not recruiting Phase 2 Interventional

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of MRF for Characterization of Brain Tumors After Radiotherapy

NCT06101069
View directory record Official record
Conditions
Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
Interventions
MRF in conjunction with IVIM MRI without contrast
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GI Neuromuscular Pathology Prospective Registry

NCT02165059
View directory record Official record
Conditions
Gastroparesis
Interventions
Surgical Full Thickness Biopsy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082
View directory record Official record
Conditions
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
381
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

NCT03875859
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Remetinostat
Drug
Lead sponsor
Kavita Sarin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 18, 2026, 5:21 PM EDT
Completed No phase listed Observational

Circulating Tumor Cells in Operative Blood

NCT02150746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Peripheral/Central Venous Blood Draw, Peritoneal Wash
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 18, 2026, 5:21 PM EDT